Impede a fever

Antibody against a conserved dengue domain could protect against all serotypes

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well. While most companies are focusing on vaccines for dengue, Visterra Inc. has licensed the mAb and believes that an immunotherapy could produce a better and more lasting way to treat and prevent infection.

Researchers have struggled to generate treatments or vaccines that work broadly in dengue fever because antibodies against one dengue serotype rarely induce long-term protection against the others. On top of that, when patients recover from dengue infection, the antibodies they develop against the first serotype can exacerbate a second infection by enhancing viral uptake into host cells.

The most advanced products in the clinic are tetravalent vaccines that include a mixture of

Read the full 1395 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers